Key Points
- CEO Herriot Tabuteau sold 49,666 shares of Axsome Therapeutics on July 1 at an average price of $240.25, totaling about $11.93 million. After the sale, his ownership fell by 87.29% to 7,229 shares.
- Axsome reported quarterly EPS of ($1.26), missing analyst expectations, while revenue of $191.2 million was roughly in line with forecasts and rose 57.4% year over year.
- Wall Street remains generally positive on the stock, with analysts assigning a Moderate Buy consensus and an average price target of $258.95, despite mixed individual ratings.
Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CEO Herriot Tabuteau sold 49,666 shares of the business's stock in a transaction on Wednesday, July 1st. The stock was sold at an average price of $240.25, for a total transaction of $11,932,256.50. Following the transaction, the chief executive officer owned 7,229 shares in the company, valued at approximately $1,736,767.25. The trade was a 87.29% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.
Herriot Tabuteau also recently made the following trade(s):
- On Tuesday, June 9th, Herriot Tabuteau sold 49,670 shares of Axsome Therapeutics stock. The stock was sold at an average price of $241.01, for a total transaction of $11,970,966.70.
Axsome Therapeutics Stock Performance
Shares of AXSM stock opened at $240.66 on Thursday. The company has a fifty day moving average price of $228.50 and a two-hundred day moving average price of $191.04. Axsome Therapeutics, Inc. has a one year low of $96.09 and a one year high of $260.19. The stock has a market cap of $12.38 billion, a P/E ratio of -64.52 and a beta of 0.60. The company has a debt-to-equity ratio of 2.27, a current ratio of 1.39 and a quick ratio of 1.32.
Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its earnings results on Monday, May 4th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.85) by ($0.41). Axsome Therapeutics had a negative net margin of 26.59% and a negative return on equity of 267.16%. The firm had revenue of $191.20 million during the quarter, compared to the consensus estimate of $191.10 million. The firm's revenue for the quarter was up 57.4% on a year-over-year basis. As a group, equities analysts predict that Axsome Therapeutics, Inc. will post -2.31 EPS for the current year.
Hedge Funds Weigh In On Axsome Therapeutics
A number of institutional investors and hedge funds have recently bought and sold shares of the company. Seven Fleet Capital Management LP raised its stake in shares of Axsome Therapeutics by 8.5% during the first quarter. Seven Fleet Capital Management LP now owns 14,055 shares of the company's stock valued at $2,376,000 after acquiring an additional 1,100 shares during the last quarter. Perceptive Advisors LLC raised its position in shares of Axsome Therapeutics by 0.7% during the first quarter. Perceptive Advisors LLC now owns 149,950 shares of the company's stock worth $25,345,000 after purchasing an additional 1,050 shares during the period. Janus Henderson Group PLC lifted its stake in shares of Axsome Therapeutics by 26.1% in the first quarter. Janus Henderson Group PLC now owns 19,052 shares of the company's stock valued at $3,219,000 after buying an additional 3,948 shares in the last quarter. Amundi acquired a new position in Axsome Therapeutics during the 1st quarter valued at about $498,000. Finally, EverSource Wealth Advisors LLC boosted its position in shares of Axsome Therapeutics by 48.0% during the first quarter. EverSource Wealth Advisors LLC now owns 512 shares of the company's stock valued at $87,000 after buying an additional 166 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company's stock.
Wall Street Analysts Forecast Growth
AXSM has been the subject of several research analyst reports. Mizuho lifted their target price on Axsome Therapeutics from $228.00 to $310.00 and gave the stock an "outperform" rating in a research note on Tuesday, May 5th. Weiss Ratings restated a "sell (d-)" rating on shares of Axsome Therapeutics in a research note on Monday, April 20th. HC Wainwright reaffirmed a "buy" rating on shares of Axsome Therapeutics in a research report on Thursday, June 4th. Truist Financial upgraded Axsome Therapeutics to a "strong-buy" rating in a report on Monday, June 15th. Finally, Needham & Company LLC raised their price target on shares of Axsome Therapeutics from $225.00 to $255.00 and gave the stock a "buy" rating in a research report on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, Axsome Therapeutics currently has a consensus rating of "Moderate Buy" and an average price target of $258.95.
View Our Latest Research Report on AXSM
About Axsome Therapeutics
(
Get Free Report)
Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.
Axsome's pipeline includes several late-stage and approved product candidates.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
